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Available online xxxxTaliglucerase alfa is an enzyme replacement therapy approved for treatment of Gaucher disease (GD) in children
and adults in several countries. This multicenter extension study assessed the efﬁcacy and safety of taliglucerase
alfa in pediatric patients with GD who were treatment-naïve (n= 10) or switched from imiglucerase (n= 5).
Patients received taliglucerase alfa 30 or 60 U/kg (treatment-naïve) or the same dose as previously treated
with imiglucerase every other week. In treatment-naïve patients, taliglucerase alfa 30 and 60 U/kg, respectively,
reduced mean spleen volume (−18.6 multiples of normal [MN] and−26.0 MN), liver volume (−0.8 MN and
−0.9 MN), and chitotriosidase activity (−72.7% and−84.4%), and increased mean Hb concentration (+2.0 g/dL
and +2.3 g/dL) and mean platelet count (+38,200/mm3 and +138,250/mm3) from baseline through 36 total
months of treatment. In patients previously treated with imiglucerase, these disease parameters remained stable
through 33 total months of treatment with taliglucerase alfa. Most adverse events were mild/moderate; treatment
was well tolerated. These ﬁndings extend the taliglucerase alfa safety and efﬁcacy proﬁle and demonstrate long-
term clinical improvement in treatment-naïve children receiving taliglucerase alfa and maintenance of disease sta-
bility in children switched to taliglucerase alfa. Treatmentwaswell-tolerated, with no new safety signals. This study
is registered at www.clinicaltrials.gov as NCT01411228.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Gaucher disease (GD) is a rare lysosomal storage disorder resulting
from mutations in the gene for the enzyme β-glucocerebrosidase [1].
Deﬁciency of β-glucocerebrosidase activity in macrophages and other
cell types results in the accumulation of glucocerebrosidase in lyso-
somes, leading to pathology, including splenomegaly, hepatomegaly,
anemia, and thrombocytopenia [2]. Patients who are diagnosed with
Type 1 GD during childhood, particularly during early childhood, tendine (C-C motif) ligand 18; ERT,
MN, multiples of normal; SE,
edek Medical Center, 12 Bayit
. This is an open access article under
ood Cells Mol. Diseases (2016to have more severe disease manifestations, more rapid disease course,
and greater burden of disease [2–7].
For patients with Type 1 (non-neuronopathic) GD, development of
enzyme replacement therapy (ERT) constitutes a major advancement
in care and has altered the natural disease course [1,2]. ERT is recom-
mended for children with GD, and early treatment may decrease the
risk of irreversible pathology [6,7].
Taliglucerase alfa is an ERT approved for adultswith Type 1GD in the
United States, Israel, Brazil, Chile, Australia, Canada, and other countries
and for pediatric patients in the United States, Israel, Australia, and
Canada, and for hematologic manifestations in pediatric patients with
Type 3 GD in Canada. Taliglucerase alfa is the ﬁrst plant cell-expressed
recombinant therapeutic protein approved by theUS Food andDrugAd-
ministration for use in humans. This agent is produced in a plant cell
suspension in disposable bioreactors [8] free of mammalian compo-
nents [8–10].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
), http://dx.doi.org/10.1016/j.bcmd.2016.10.005
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spectively in pediatric-focused studies. Prospective clinical studies
have investigated the safety and efﬁcacy of taliglucerase alfa in pediatric
patients with GD. Study PB-06-005 assessed the efﬁcacy and safety of
taliglucerase alfa at 2 dose levels, 30 U/kg and 60 U/kg, in treatment-
naïve children with GD (n = 11) during 12 months of treatment [11].
Findings showed clinically signiﬁcant improvements in spleen and
liver volumes, Hb levels, platelet counts, and chitotriosidase activity
[11]. Study PB-06-002 assessed the safety and efﬁcacy of switching
from imiglucerase to the same dose of taliglucerase alfa in pediatric
(n= 5) and adult (n= 26) patients with stable GD [12]. Findings indi-
cated that all patients, including the pediatric patients, remained clini-
cally stable through 9 months of treatment following the switch from
imiglucerase to taliglucerase alfa [12]. Pediatric patients who completed
PB-06-005 and PB-06-002were eligible to enroll in extension study PB-
06-006. Here, we report the long-term safety and efﬁcacy ﬁndings for
pediatric patients receiving taliglucerase alfa in study PB-06-006
through 36 months of treatment.
2. Materials and methods
2.1. Study design
PB-06-006 (NCT01411228) was a multicenter extension study de-
signed to evaluate the long-term efﬁcacy and safety of taliglucerase
alfa in patientswith GDwhowere 2 to b18 years old andhad completed
PB-06-005 (treatment naïve; NCT01132690) or PB-06-002 (treatment
switch from imiglucerase to taliglucerase alfa; NCT00712348). Protocol
details for PB-06-005 and PB-06-002have been reported previously [11,
12]. PB-06-005 was a double-blind study that enrolled treatment-naïve
patients 2 to b18 years old and randomized them to 12 months of
taliglucerase alfa 30 or 60 U/kg. PB-06-002 was an open-label study
that enrolled adult and pediatric patients whowere identiﬁed as having
a stable clinical GD presentation and had been receiving ERT for
≥2 years on a stable maintenance dose of imiglucerase for 6 months;
these patients were switched from imiglucerase to taliglucerase alfa at
the same dose and received taliglucerase alfa for 9 months.
In PB-06-006, patients continued receiving taliglucerase alfa every
other week for up to an additional 24 months of treatment at the
same dose the patient received in the previous taliglucerase alfa study.
Patients from PB-06-005 received up to 36 total months of treatment
(12 months of double-blind treatment in PB-06-005 followed by 12
months of double-blind treatment in PB-06-006 and an additional 12
months of open-label treatment in PB-06-006), and patients from PB-
06-002 received up to 33 total months of open-label treatment. Based
on results from previous and current studies conﬁrming the efﬁcacy
and safety of taliglucerase alfa and to ease the burden of clinical studies
for pediatric patients, the sponsor decided to close the extension study
early. Two patients who switched from imiglucerase (30-233 and 92-
232) had not completed 24 months of treatment in PB-06-006 at the
time of study closure; they completed 18 months of treatment in
study PB-06-006 (27 total months of treatment) and continued treat-
ment under a compassionate use program.
This study was conducted in accordance with Good Clinical Practice
guidelines and according to the International Council for Harmonisation
Harmonized Tripartite Guideline and all local regulations. The protocol
and informed consent formwere reviewed and approved by the appro-
priate institutional review board/ethics committee associated with the
study site. Informed written consent was obtained from each patient
and/or the parent or guardian.
2.2. Patients
Inclusion criteria for PB-06-006 were completion of PB-06-005 or
PB-06-002 and written informed consent. Inclusion criteria for PB-06-
005 and PB-06-002 have been published [11,12]. Exclusion criteriaPlease cite this article as: A. Zimran, et al., Blood Cells Mol. Diseases (2016were presence of severe complex neurological signs and symptoms
characteristic of neuronopathic GD other than long-standing oculomo-
tor gaze palsy; anymedical, emotional, behavioral, or psychological con-
dition that would interfere with study participation; and current use of
another investigational agent.2.3. Efﬁcacy assessments
Spleen and liver volumes were measured using a volumetric MRI
technique employing automatic segmentation software methodology,
which allows for lower variability and more precise monitoring of
changes over time than traditional, fully manual methods [13]. Volume
was calculated in multiples of normal (MN), where normal spleen vol-
ume is 2 mL/kg and normal liver volume is 25 mL/kg. Hb concentration
and platelet countmeasurements were performed by local laboratories.
Anemiawas deﬁned as a serumHb level b 11.0 g/dL for patients 0.5 to
b5 years old, b11.5 g/dL for patients 5 to b12 years old, b12.0 g/dL for
patients 12 to b15 years old, b12.0 g/dL for female (b11.0 g/dL if preg-
nant), and b13.0 g/dL for male patients ≥15 years old. Assays for
chitotriosidase activity and levels of CCL18were performed by a central
laboratory (Academic Medical Center, Amsterdam, The Netherlands).
Due to assay variability and for biomarker measurement consistency,
the baseline samples obtained during the original studies PB-06-005
or PB-06-002 were re-run with the on-treatment samples for each
time point in study PB-06-006 for chitotriosidase activity and CCL18
concentration. The last biomarkermeasurementwas at 30 total months
of treatment for patients switched from imiglucerase to taliglucerase
alfa.
Exploratory end points included changes in height and weight,
bone age (by plain radiography of the left hand and wrist), occur-
rence of bone crises (included in safety analysis), change in pubertal
status (by Tanner stage), and change in quality of life in patients
from PB-06-005 using the Child Health Questionnaire™ Parent
Form-28 [14].2.4. Safety
Safety assessments included adverse events (AEs), vital signs, labo-
ratory tests, and anti-taliglucerase alfa antibodies performed as previ-
ously described [11]. Clinical signs and symptoms reported during the
studywere evaluated to identify possible anaphylaxis in a post hoc anal-
ysis based on Sampson-deﬁned criteria for determining anaphylaxis
[15]. Bone events, including bone crises, were included in the analysis
of AEs. The AEs described herein are thosewith onset that occurred dur-
ing PB-06-006.2.5. Statistical analysis
For each parameter, efﬁcacy analyses included patients for whom
data were available at each time point. Time points for efﬁcacy assess-
ments were counted continuously from baselines in PB-06-005 or PB-
06-002 through PB-06-006 and are denoted by total months of
taliglucerase alfa treatment relative to baseline.
Descriptive statistics for continuous variables, sample size (n),
and mean and its standard error (SE), standard deviation, median,
and range were determined; for categorical variables, count and
percentages were calculated. Because of the small size of the
study, inferential statistics were not performed for testing the
change from baseline and/or for comparison between or among
treatment groups. For continuous values that are summarized
(e.g., demographics), standard deviation is provided; SE is present-
ed for continuous values that may be compared (e.g., baseline and
on-treatment values).), http://dx.doi.org/10.1016/j.bcmd.2016.10.005
Table 1
Baseline patient demographics.
Treatment-naïve
taliglucerase alfa
30 U/kg (n = 5)
Treatment-naïve
taliglucerase alfa
60 U/kg (n = 5)
Switch from
imiglucerase to
taliglucerase alfa
(n = 5)
Age, years
Mean (SD) 8.6 (3.8) 6.6 (3.1) 13.0 (4.1)
Median (range) 8.0 (3−13) 8.0 (2−10) 15.0 (6–16)
Sex, n (%)
Male 3 (60.0) 4 (80.0) 3 (60.0)
Female 2 (40.0) 1 (20.0) 2 (40.0)
Race, n (%)
Caucasian 5 (100.0) 4 (80.0) 4 (80.0)
Asian-Paciﬁc Islander 0 0 1 (20.0)
Other 0 1 (20.0) 0
Ethnicity, n (%)
Hispanic or Latino 3 (60.0) 1 (20.0) 2 (40.0)
Not Hispanic or Latino 2 (40.0) 4 (80.0) 3 (60.0)
Religiona
Jewish–Ashkenazi, n
(%)
0 2 (40.0) 0
Jewish–Non-Ashkenazi,
n (%)
0 0 0
Non-Jewish, n (%) 5 (100.0) 3 (60.0) 3 (100.0)
SD, standard deviation.
a Religion data available for 3 of the 5 patients originally from study PB-06-002.
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3.1. Patients
The patient disposition is shown in Fig. 1. Of the 11 patients who
completed PB-06-005 (treatment-naïve), 1 patient (10-5003) did not
enroll in PB-06-006 because of worsening of a disease characteristic,
cardiac valve involvement requiring intervention; this patient contin-
ued taliglucerase alfa treatment in a compassionate use program. Of
the 10 patients from PB-06-005 who enrolled in PB-06-006, 9 complet-
ed 36 total months of treatment; 1 patient (10-5001; 60 U/kg) with-
drew voluntarily after 66 total infusions in studies PB-06-005 and PB-
06-006 for personal reasons (parent was unhappy with the child's
growth). All 5 patients who were previously treated with imiglucerase
and completed PB-06-002 enrolled in PB-06-006; of these, 1 patient
(30-231) was lost to follow-up after 59 total infusions in studies PB-
06-002 and PB-06-006. Because the studywas closed prematurely, 2 pa-
tients (30-233, 92-232) completed 18 months of treatment in PB-06-
006 (27 total months of treatment with taliglucerase alfa) and entered
into a compassionate use program. Patient demographics and baseline
disease characteristics are listed in Tables 1 and 2, respectively.
3.2. Extent of exposure
Five treatment-naïve patients randomized to taliglucerase alfa
30 U/kg at the start of PB-06-005 received a mean dose of 39.1 U/kg
(range, 32.7–50.1 U/kg) for a mean duration of 24.0 months (range,
23.9–24.2 months) during PB-06-006. The 5 treatment-naïve patients
randomized to taliglucerase alfa 60 U/kg in PB-06-005 received a
mean dose of 72.4 U/kg (range, 67.2–78.4 U/kg) for a mean duration
of 22.7 months (range, 17.7–24.2 months) during PB-06-006. The 5 pa-
tientswho switched from imiglucerase to the samedose of taliglucerase*Patient had GD Type 3c and cardiac involvement requiring intervention due
†Patients did not reach 33 total months of treatment due to early closure o
Extension Study PB-06-Original Study
9 12
PB-06-002
• n = 5 enrolled
• n = 5 completed
PB-06-006
• n = 5 enrolled
Not recruiteda
• n = 1
• Continued with compassionate 
use program
PB-06-006
• n = 10 enrolled
Months
PB-06-005
• n = 11 enrolled
• n = 11 completed
Fig. 1. Patient disposition. a. Patient had Type 3c Gaucher disease and cardiac involvement req
treatment due to early closure of study.
Please cite this article as: A. Zimran, et al., Blood Cells Mol. Diseases (2016alfa received amean dose 43.0 U/kg (range, 25.5–62.6 U/kg) for a mean
duration of 20.5 months (range, 17.9–24.2 months) during PB-06-006.
3.3. Organ volumes
Mean and individual spleen volumes for treatment-naïve patients
improved over 36 months of therapy with taliglucerase alfa in both to decompensation.
f study (see Methods)
006
24 33 36
Completed 
extension 
treatment
• n = 2
Completed 
extension 
treatment
• n = 9
Dropout
• n = 1
• (10-5001)
Lost to 
follow-up
• n = 1 
• (30-231)
Continued with 
compassionate use 
program
• n = 2
Completed 27 months
of treatmentb
• n = 2 
• (30-233; 92-232)
uiring intervention due to decompensation. b. Patients did not reach 33 total months of
), http://dx.doi.org/10.1016/j.bcmd.2016.10.005
Table 2
Disease parameters.
Treatment-naïve
taliglucerase alfa 30 U/kg
(n = 5)
Treatment-naïve
taliglucerase alfa 60 U/kg
(n = 5)
Switch from imiglucerase to
taliglucerase alfa
(n = 5)
Spleen volume
Baselinea, MN n = 5 n = 5 n = 5
Mean (SE) 23.9 (5.7) 29.4 (10.8) 4.1 (1.2)
Median (range) 27.0 (9.0, 41.2) 18.4 (10.0, 69.3) 3.1 (1.7, 7.9)
End of studyb, MN n = 4 n = 3 n = 2
Mean (SE) 9.0 (2.3) 6.6 (1.3) 1.7 (0.1)
Median (range) 8.3 (4.4, 15.1) 5.9 (4.8, 9.1) (1.6, 1.8)
Change, MNc
Mean (SE) −18.6 (3.5) −26.0 (17.2) −0.1 (0.0)
Median (range) −19.3 (−26.1,−9.6) −12.5 (−60.2,−5.2) (−0.1,−0.1)
% Changec
Mean (SE) −67.8 (2.6) −68.9 (10.0) −5.3 (0.2)
Median (range) −66.5 (−74.9,−63.3) −67.8 (−86.8,−52.1) (−5.5,−5.2)
Liver volume
Baselinea, MN n = 5 n = 5 n = 5
Mean (SE) 1.9 (0.2) 2.2 (0.2) 1.3 (0.1)
Median (range) 1.8 (1.4, 2.7) 2.1 (1.8, 3.0) 1.1 (1.0, 1.6)
End of studyb, MN n = 4 n = 3 n = 2
Mean (SE) 1.3 (0.1) 1.5 (0.0) 0.9 (0.0)
Median (range) 1.2 (1.2, 1.5) 1.5 (1.4, 1.6) (0.9, 1.0)
Change, MNc
Mean (SE) −0.8 (0.1) −0.9 (0.3) −0.1 (0.0)
Median (range) −0.6 (−1.2,−0.6) −0.8 (−1.4,−0.4) (−0.1,−0.1)
% Changec
Mean (SE) −37.0 (2.7) −34.3 (7.5) −8.8 (1.5)
Median (range) −35.0 (−44.9,−33.1) −34.2 (−47.3,−21.3) (−10.3,−7.2)
Hb concentration
Baselinea, g/dL n = 5 n = 5 n = 5
Mean (SE) 11.2 (0.8) 10.6 (0.6) 13.5 (0.2)
Median (range) 11.3 (8.2, 13.2) 11.1 (9.1, 12.3) 13.4 (12.9, 14.2)
End of studyb, g/dL n = 5 n = 4 n = 2
Mean (SE) 13.2 (0.5) 12.7 (0.7) 14.5 (0.6)
Median (range) 12.8 (12.2, 14.9) 12.4 (11.5, 14.6) (13.9, 15.0)
Change, g/dLc
Mean (SE) +2.0 (0.6) +2.3 (0.7) +0.5 (0.3)
Median (range) +1.7 (0.6, 4.0) +2.8 (0.4, 3.3) (0.1, 0.8)
% Changec
Mean (SE) +19.7 (7.6) +23.3 (7.7) +3.3 (2.4)
Median (range) +14.3 (4.9, 48.8) +26.7 (3.6, 36.3) (0.9, 5.6)
Platelet counts
Baselinea, /mm3 n = 5 n = 5 n = 5
Mean (SE) 182,000 (27,009) 99,600 (19,185) 164,587 (17,321)
Median (range) 172,000 (116,000, 273,000) 80,000 (76,000, 176,000) 146,500 (119,667, 206,000)
End of studyb, /mm3 n = 5 n = 4 n = 2
Mean (SE) 220,020 (29,231) 243,750 (18,585) 210,000 (10,000)
Median (range) 194,000 (153,000, 324,000) 239,500 (206,000, 290,000) (200,000, 220,000)
Change, /mm3c
Mean (SE) 38,200 (12,265) 138,250 (27,143) 4700 (9300)
Median (range) 34,000 (8000, 78,000) 131,000 (80,000, 211,000) (−4600, 14,000)
% Changec
Mean (SE) +23.9 (11.1) +156.6 (45.2) +2.3 (4.5)
Median (range) +16.7 (6.0, 67.0) +156.9 (45.0, 267.0) (−2.0, 7.0)
Chitotriosidase activity
Baselinea,d, nmol/mL·h n = 5 n = 4 n = 5
Mean (SE) 30,783 (7948) 34,968 (10,464) 10,432 (6221)
Median (range) 26,912 (6575, 53,415) 30,924 (16,666, 61,360) 1991 (120, 30,952)
End of studyb, nmol/mL·h n = 5 n = 3 n = 2
Mean (SE) 7640.6 (2937.6) 5204.0 (2566.5) 370.5 (192.5)
Median (range) 5211.0 (2032, 17,874) 5347.0 (689, 9576) (178.0, 563.0)
% Changec
Mean (SE) −72.7 (7.3) −84.4 (6.6) 97.1 (48.8)
Median (range) −66.5 (−92.0,−57.0) −84.4 (−96.0,−73.0) (48.0, 146.0)
CCL18 concentration
Baselinea,d, ng/mL n = 5 n = 5 n = 5
Mean (SE) 1320.4 (436.8) 1309.8 (360.7) 384.0 (181.7)
Median (range) 1135.0 (344.0, 2900.0) 1153.0 (577.0, 2679.0) 253.0 (32.0, 962.0)
End of studyb, ng/mL n = 5 n = 4 n = 2
Mean (SE) 369.2 (136.7) 290.3 (109.0) 38.0 (8.0)
Median (range) 204.0 (117.0, 825.0) 270.0 (47.0, 574.0) (30.0, 46.0)
% Changec
Mean (SE) −67.7 (9.3) −73.2 (7.9) 10.8 (17.0)
Median (range) −71.6 (−89.0,−41.0) −73.8 (−92.0,−53.0) (−6.0, 28.0)
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Fig. 2.Mean organ volume through up to 36 total months of taliglucerase alfa treatment. (A) Mean spleen volume for patients who started taliglucerase alfa treatment in PB-06-005
(previously treatment-naïve). (B) Mean spleen volume for patients who started taliglucerase alfa in PB-06-005 (switch from imiglucerase). (C) Mean liver volume for patients
originally from PB-06-005. (D) Mean liver volume for patients originally from PB-06-002. Spleen volume is expressed as multiples of normal (MN), where normal spleen volume = 2
mL/kg·body weight (kg). Liver volume is expressed as MN where normal liver volume = 25 mL/kg·body weight (kg). Baseline values were those measured at baseline (Visit 1) in PB-
06-005 for treatment-naïve patients and in PB-06-002 for patients who switched treatment. In the treatment-naïve population, 2 patients (10-5002 [30 U/kg] and 10-5007 [60 U/kg])
did not have organ volume measurements during PB-06-006 (24 and 36 months) because sedation during MRI was not permitted, and 1 patient (10-5001 [60 U/kg]) did not have
organ volume measurements at 36 months because the patient withdrew from the study. In the group who switched from imiglucerase, 3 patients did not have measurements at 33
months: 2 patients (30-233 and 92-232) due to early study closure and 1 patient (30-231) who was lost to follow-up. Error bars represent standard error.
5A. Zimran et al. / Blood Cells, Molecules and Diseases xxx (2016) xxx–xxxdose groups (Fig. 2a, Table 2). In patients receiving 30 U/kg, mean
spleen volume decreased from 23.9 MN at baseline to 9.0 MN at 36
months; in patients receiving 60 U/kg, mean spleen volume decreased
from 29.4 MN to 6.6 MN. Spleen volumes for the patients who switched
from imiglucerase improved or remained stable through 33 months of
therapy (Fig. 2b, Table 2).
Mean and individual liver volumes for treatment-naïve patients im-
proved during the 36 months of treatment with taliglucerase alfa in
both dose groups (Fig. 2c, Table 2). Mean liver volume was 1.9 MN atNotes to Table:
CCL18, chemokine (C-Cmotif) ligand 18; Hb, hemoglobin;MN,multiples of normal, where norm
times body weight (kg); SE, standard error.
For explanation of patient numbers, refer to Figs. 2–4 (legends).
a Baseline is that from the study the patient participated in before enrolling in PB-06-006 (i
from imiglucerase).
b For treatment-naïve patients, values represent those achieved after 36 total months of treat
achieved after 33 total months of treatment for all parameters except chitotriosidase and CCL1
c Absolute change and percent change were calculated based on baseline and end-of-study
d Due to assay variability, the baseline samples obtained during original studies PB-06-002 a
Please cite this article as: A. Zimran, et al., Blood Cells Mol. Diseases (2016baseline and 1.3 MN at 36 months for patients receiving 30 U/kg and
2.2 MN at baseline and 1.5 MN at 36 months for patients receiving
60 U/kg. In the patients who switched from imiglucerase, liver volumes
remained stable (Fig. 2d, Table 2).
3.4. Hematologic parameters
In treatment-naïve patients, mean and individual Hb levels im-
proved over 36 months of treatment with taliglucerase alfa (Fig. 3a,al spleen volume is 2mL/kg times bodyweight (kg) and normal liver volume is 25mL/kg
.e., PB-06-005 for treatment-naïve patients and PB-06-002 for the patients who switched
ment; for patients switched from imiglucerase to taliglucerase alfa, values represent those
8, which was 30 total months of treatment.
values for patients remaining at the end of the study.
nd PB-06-005 were re-run with the on-treatment samples.
), http://dx.doi.org/10.1016/j.bcmd.2016.10.005
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Fig. 3.Mean hematologic parameters through up to 36 total months of taliglucerase alfa treatment. (A) Mean Hb values for patients who started taliglucerase alfa treatment in PB-06-005
(previously treatment-naïve). (B) Mean Hb values for patients who started taliglucerase alfa in PB-06-005 (switch from imiglucerase). (C) Mean platelet counts for patients originally in
PB-06-005. (D) Mean platelet counts for patients originally in PB-06-002. Baseline values were those measured at baseline (Visit 1) in PB-06-005 for treatment-naïve patients and in PB-
06-002 for patients who switched from imiglucerase. In the treatment-naïve population, 1 patient (10-5001; 60 U/kg) did not havemeasurements at 30 and 36months due towithdrawal
from the study. In the groupwho switched from imiglucerase, 3 patients did not havemeasurements at 33months: 2 patients (30-233 and 92-232) due to early study closure and 1 patient
(30-231) who was lost to follow-up. Error bars represent SE.
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13.2 g/dL at 36 months for patients receiving 30 U/kg and 10.6 g/dL
at baseline and 12.7 g/dL for patients receiving 60 U/kg. Of the 10
treatment-naïve patients, 7 had anemia at baseline. In this subset
of patients with anemia, 6 completed 36 months of treatment; the
mean (SE) increase in Hb concentration from baseline to 36 months
was +2.5 (0.7) g/dL (+26.9% [11.0%], n = 3) for those receiving
30 U/kg and +2.3 (1.0) g/dL (+24.9% [10.6%], n = 3) for those re-
ceiving 60 U/kg. All 7 patients with anemia demonstrated improve-
ment in Hb level throughout the study, and none had anemia at
study end. In the patients who switched from imiglucerase, Hb levels
improved or remained stable through 33 months of taliglucerase alfa
treatment (Fig. 3b, Table 2).
Mean platelet counts improved during 36 months of therapy with
taliglucerase alfa in treatment-naïve patients (Fig. 3c, Table 2). Mean
platelet counts were 182,000/mm3 at baseline and 220,000/mm3 at 36
months for patients receiving 30 U/kg and 99,600/mm3 at baseline
and 243,750/mm3 at 36 months for patients receiving 60 U/kg. Some
patients showed variation over time in platelet count (Fig. 3c). In pa-
tients who switched from imiglucerase, mean platelet counts improved
or remained stable during the 33 months of therapy with taliglucerase
alfa (Fig. 3d, Table 2). Some variation over timewas observed in platelet
counts for individual patients (Fig. 3d).Please cite this article as: A. Zimran, et al., Blood Cells Mol. Diseases (20163.5. Biomarkers
In treatment-naïve patients, mean and individual chitotriosidase
activity (Fig. 4a, Table 2) and chemokine (C-C motif) ligand 18
(CCL18) concentration (Fig. 4c, Table 2) improved over 36 months of
treatment with taliglucerase alfa, with most of the improvement
noted by 12 months. Mean (SE) percent changes in chitotriosidase ac-
tivity and CCL18 concentration from baseline to 36 months were
−72.7% (7.3%) and−67.7% (9.3%), respectively, in patients receiving
30 U/kg and−84.4% (6.6%) and−73.2% (7.9%), respectively, in patients
receiving 60 U/kg. In patients who switched from imiglucerase, mean
chitotriosidase activity and CCL18 concentration improved during
taliglucerase alfa treatment, with some individual variation (Fig. 4b
and d).3.6. Growth and development
With regard to growth and development, it may be worthwhile to
note that the patients in the 60 U/kg dose group were somewhat
younger overall (mean 6.6 years; range 2–10 years) than patients
in the 30 U/kg dose group (mean 8.6 years; range 3–13 years)
(Table 1).), http://dx.doi.org/10.1016/j.bcmd.2016.10.005
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Fig. 4.Biomarkers frombaseline through up to 36 totalmonths of taliglucerase alfa treatment. (A)Mean chitotriosidase activity (absolute values) for patientswho started taliglucerase alfa
in PB-06-005 (treatment-naïve). (B) Mean chitotriosidase activity (absolute values) for patients who started taliglucerase alfa in PB-06-002 (treatment switch from imiglucerase).
(C) Mean chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) (CCL18) (absolute values) for patients originally from PB-06-005. (D) Mean CCL18 levels (absolute
values) for patients originally from PB-06-002. Baseline values were those measured at baseline (Visit 1) in PB-06-005 for treatment-naïve patients and in PB-06-002 for patients who
switched treatment. In the treatment-naïve population, 1 patient (91-5010 [60 U/kg]) had no measurable chitotriosidase activity at baseline and was not included in the
chitotriosidase analysis; 1 patient (10-5001 [60-U/kg]) did not have measurements at 30 (CCL18) or 36 (CCL18 and chitotriosidase) months due to study withdrawal. In the group
who switched from imiglucerase, measurements were not available at 33 months and 3 patients did not have measurements at the available 30 month time point: 2 patients (30-233
and 92-232) due to early study closure and 1 patient (30-231) who was lost to follow-up. Error bars represent standard error.
7A. Zimran et al. / Blood Cells, Molecules and Diseases xxx (2016) xxx–xxxAll patients exhibited growth during this study. Mean (SE) percent
change in height from baseline to 36 months was +12.4% (2.6%) with
30 U/kg (n = 4) and +19.2% (3.0%) with 60 U/kg (n = 4) in
treatment-naïve patients, and +5.0% (3.1%) at 33 months in patients
who switched from imiglucerase (n = 2). Analysis of height velocity
through the end of the study (or last visit if a patient did not complete
the study) revealed mean (SE) rates of 5.5 (0.8) cm/year with 30 U/kg
(n = 5) and 6.7 (0.6) cm/year with 60 U/kg (n = 5) in treatment-
naïve patients and 2.5 (0.7) cm/year (n= 5) in patients who switched
from imiglucerase. Mean (SE) percent change in weight from baseline
to 36 months was 39.8% (4.6%) with 30 U/kg (n= 5) and 35.0% (3.6%)
with 60 U/kg (n = 4) in treatment-naïve patients and 18.2% (8.8%) in
patients who switched from imiglucerase (n = 2) after 33 months of
treatment.
The pubertal status (assessed by Tanner stage) did not change during
this extension study formost patients. All treatment-naive patientswere
≤10 years of age at baseline; 9 patients were at stage 1 and 1 patient was
at stage 3. Two patients treated with taliglucerase alfa 30 U/kg had pu-
bertal advancement; 1 patient (91-5008) progressed from Tanner stage
1 at baseline to stage 2 by 12 months and continued to advance toPlease cite this article as: A. Zimran, et al., Blood Cells Mol. Diseases (2016stage 3 by the end of this study. The other patient (91-5009) advanced
fromTanner stage 3 to stage 4 by 18months. Twopatientswho switched
from imiglucerase (14-229 and 14-230) advanced from Tanner stage 3
and 2, respectively, to stage 4 by the end of the study.
Bone age increased from baseline by a mean (SE) of 3.6 (0.9) years
(range, 1.5–6.5 years) over the 36 months of the combined study for
the 30 U/kg cohort (n = 5) and by 4.6 (0.6) years (range, 3.0–5.5
years) for the 60 U/kg cohort (n = 4) in treatment-naïve patients. For
3 patients who switched from imiglucerase and had baseline bone age
measurements, bone age increased by a mean (SE) of 2.3 (0.3) years
(range, 2.0–3.0 years) by 24months (no data available over 33months).
Quality of life was assessed in treatment-naïve patients. Findings
from the Child Health Questionnaire™ Parent Form-28 showed that
more parents/guardians rated their children's global health as “very
good” at 36 months (7/9) than at baseline (1/9). Parental assessment
of a child's global health improved from “fair” to “very good” for 3 pa-
tients and from “good” to “very good” for 3 patients. At baseline, 2 of 9
parents/guardians rated their children's health as “much better” or
“somewhat better” than 1 year ago; at 36months, 6 of 9 parents/guard-
ians rated their children's health as “much better” or “somewhat better”), http://dx.doi.org/10.1016/j.bcmd.2016.10.005
8 A. Zimran et al. / Blood Cells, Molecules and Diseases xxx (2016) xxx–xxxthan 1 year ago. At 36months, 1 of 9 parents/guardians had “quite a bit”
or “a lot” of worry about their children's physical health compared with
5 of 9 parents/guardians at baseline. Furthermore, at 36 months, 1 of 9
parents/guardians said they were limited a lot in the amount of time
available for their own needs compared with 3 of 9 parents/guardians
at baseline.
3.7. Safety
Taliglucerase alfa treatment was well tolerated. All AEs were mild to
moderate in severity (Table 3). The most common AEs (≥3 of 15 total
patients) reported during extension study PB-06-006 were cough
(n=4), headache (n=4), upper respiratory tract infection (n=4), ab-
dominal pain (n= 3), Dengue fever (n= 3), diarrhea (n= 3), lymph-
edema (n=3), nasopharyngitis (n=3), and pain in extremity (n=3).
No patient had a change to his/her taliglucerase alfa dose because of an
AE. One AEwas assessed as possibly related to study drug (Table 3); this
eventwasmild (Grade 1) infusion site pain in a treatment-naïve patient
(11-5004; 60 U/kg) and resolved on the same day. No deaths occurred
during the study, and no patients were discontinued from the study be-
cause of an AE. One serious AE occurred (Table 3), a case of Grade 2Den-
gue fever requiring hospitalization in a treatment-naïve patient (11-
5004); the event resolved within 5 weeks and was considered not to
be related to study drug. Most laboratory hematology and biochemistry
parameters remained at normal levels at the end of the study, and there
were no clinically meaningful laboratory abnormalities. No patient ex-
perienced a bone crisis during the extension study.
3.8. Immunogenicity
No episodes of anaphylaxis occurred during study PB-06-006. Of the
treatment-naive patients who tested positive for the presence of anti-
taliglucerase alfa IgG antibodies during PB-06-005, 1 patient (91-
5009; 30 U/kg) remained antibody-positive through extension study
PB-06-006 and tested positive for neutralizing antibodies based on the
in vitro enzymatic activity assay. For this patient, spleen and liver vol-
umes, Hb levels, platelet counts, chitotriosidase activity, and CCL18
levels continued to improve through the 36 months of taliglucerase
alfa treatment. Four weeks into the extension study, the patient was di-
agnosed with Dengue fever; the event was considered mild in severity,
resolvedwithin 2 days, andwas not considered by the investigator to be
related to treatment. All 5 patients who switched from imiglucerase
tested negative for anti-taliglucerase alfa IgG antibodies during the ex-
tension study.
3.9. Type 3 GD
Two children in this extension study had Type 3 GD, 1 treatment-
naïve patient and 1 switched from imiglucerase. Patient 10-5002
(30 U/kg) was 3 years old at entry into the parent study (PB-06-005)
and continued into the extension study, completing 36 total months
of treatment. Although the patient did not have an organ volumeTable 3
Adverse events occurring in study PB-06-006.a
No. of adverse events
(no. of patients)
Percentage of total
adverse events
Total adverse events 126 (15) 100.0
Mild or moderate 126 100.0
Severe/very severe 0 0
Treatment-relatedb 1 0.8
Seriousc 1 0.8
Serious treatment-related 0 0
a Those occurring in extension study PB-06-006.
b Tenderness at the infusion site.
c Hospitalization due Dengue fever.
Please cite this article as: A. Zimran, et al., Blood Cells Mol. Diseases (2016measurement during the extension studybecause sedationwasnot per-
mitted duringMRI evaluations at the patient's study site,measurements
made at the end of the preceding study indicated that spleen volume
decreased from 9.0 to 7.1 MN and liver volume decreased from 1.4 to
1.2 MN by 12 months (end of study PB-06-005). At 36 months, his Hb
level increased to 12.8 mg/dL from a baseline of 12.2 mg/dL and platelet
count increased to 153,000/mm3 from a baseline of 145,000/mm3;
chitotriosidase activity decreased 57% and CCL18 decreased by 41%
from baseline. The patient experienced 10 mild AEs during the exten-
sion study, none of which was considered to be treatment-related. He
had normal echocardiography and none of his laboratory results were
clinically signiﬁcant or reported as an AE. Patient 92-232 was a 6-
year-old male at entry into original study PB-06-002 and continued
into the extension study, completing 27 total months of treatment be-
fore entering a compassionate use program for taliglucerase alfa. The
patient was diagnosed by his physician as having Type 1 GD, but was
homozygous for the c.1448TNC (L444P) mutation in the GBA gene, sug-
gesting that he has Type 3 GD, although during the time of the clinical
trials, neurologic ﬁndings had not been noted. At the time of last obser-
vation, spleen volume decreased from 7.9 MN at baseline to 5.6 MN,
liver volume decreased from 1.6 MN at baseline to 1.3 MN, Hb level in-
creased from12.9mg/dL at baseline to 13.1mg/dL, chitotriosidase activ-
ity decreased 43%, and CCL18 decreased by 23% from baseline. Platelet
count had increased from 140,000/mm3 to 282,000/mm3 by 24 total
months of treatment but was 132,000/mm3 at last observation. The pa-
tient experienced 12 mild AEs during the extension study, none of
which was considered to be treatment-related. Exclusion of the data
from these 2 patients from safety and efﬁcacy analyses did not signiﬁ-
cantly affect the results of this extension study (data not shown).
4. Discussion
This study extends the safety and efﬁcacy ﬁndings of taliglucerase
alfa from PB-06-005, a study notable for its sole focus on pediatric pa-
tients with GD [11] and provides longer term data on the pediatric pa-
tients from PB-06-002 who were switched from imiglucerase to
taliglucerase alfa [12]. Treatment with taliglucerase alfa 30 or 60 U/kg
resulted in continuous improvements in visceral and hematologic
disease parameters and biomarkers through 36 total months in
treatment-naïve children and was similar to that shown in adult pa-
tients with GD; stability of visceral and hematologic disease parameters
and biomarkers was maintained during 33 months of treatment with
taliglucerase alfa in the cohort of children who switched from
imiglucerase.
Improvements in visceral and hematologic manifestations of GD
demonstrated by pediatric patients receiving long-term therapy with
taliglucerase alfa in this study were consistent with those observed for
adult and pediatric patients with GD receiving long-term treatment
with imiglucerase and velaglucerase alfa in other studies [16,17]. Efﬁca-
cy and safety ﬁndings for pediatric patients were also similar to those
for adults with GD receiving long-term therapy with taliglucerase alfa
[18,19].
Anemia is common in children with GD, affecting≈40% of patients,
and tends to be more severe in patients who present at the youngest
ages [7]. Anemia in patients with GD has been largely attributed to
hypersplenism and replacement of bone marrow by Gaucher cells [1,
2], which may contribute to fatigue and weakness and may necessitate
blood transfusions [5]. Seven of the 10 treatment-naïve patients had
anemia at baseline; by study end, the anemia had resolved in all 7 pa-
tients. Aspects of GD unique to pediatric patients include growth inhibi-
tion and pubertal delay [3–7,20]. Exploratory analyses looked at the
effects of taliglucerase alfa on growth, pubertal development (treat-
ment-naïve patients only), and bone age. All patients continued to
grow and increase in height and weight during the study, and assess-
ments ofmean bone age and pubertal status also showed improvement.
Bone disease in patients with GD can start as early in childhood as), http://dx.doi.org/10.1016/j.bcmd.2016.10.005
9A. Zimran et al. / Blood Cells, Molecules and Diseases xxx (2016) xxx–xxx5 years [20], and progressive skeletal pathology in patients with GD is
highly debilitating [2]. As noted in the results, none of the patients in
the extension study experienced a bone crisis.
The ﬁndings from this study extend the safety proﬁle observed in
pediatric patients receiving taliglucerase alfa, which were similar to
those in the original studies (PB-06-005 and PB-06-002) [11,12]. Treat-
ment was generally well tolerated. No severe AEs occurred, no serious,
treatment-related AEs were observed, and no patients discontinued be-
cause of an AE. There were no differences in the safety proﬁle for the
30 U/kg and 60 U/kg doses in this extension study. Although some pa-
tients tested positive for anti-taliglucerase alfa antibodies at different
points in PB-06-005 and PB-06-002, only 1 patient (91-5009) tested
positive during the extension study (months 18, 24, 30, and 36); how-
ever, this patient demonstrated continuous improvement from baseline
in hematologic parameters, organ volumes, and biomarkers through 36
months of treatment. The sustained improvement in the treatment-
naïve patients and maintained stability of disease parameters in pa-
tients who switched from imiglucerase suggest a lack of substantial im-
pact of the positive anti-taliglucerase alfa antibody results on treatment
efﬁcacy.
This study included 2 patients with Type 3 GD (10-5002 and 92-
232). In general, these patients experienced improvements in the vis-
ceral, hematologic, and biomarker parameters assessed. Sensitivity
analyses demonstrated that inclusion of these patients had no signiﬁ-
cant impact on the long-term efﬁcacy and safety analyses of patients
with Type 1 GD. Other sensitivity analyses demonstrated that patient
discontinuations had no signiﬁcant impact on the long-term efﬁcacy
and safety ﬁndings.
ERT is a standard of care for the non-neuronopathic features of Type
3 GD [21]. The European Working Group on Gaucher Disease recom-
mends that ERT be initiated as soon as possible for patients with Type
3GDbecause of documented clinical improvements in visceral, hemato-
logic, and skeletal disease manifestations [22]. However, the only coun-
try to date in which taliglucerase alfa is approved for Type 3 GD is
Canada. Because of the restriction of approved use to Type 1 GD, pa-
tients in many countries encounter difﬁculties in obtaining reimburse-
ment for treatment costs.
Taliglucerase alfa does is not approved in the European Union
despite a positive risk-beneﬁt assessment by the European Medicines
Agency because that body granted orphan drug status and marketing
exclusivity to velaglucerase alfa, another ERT for GD, in 2010.
Taliglucerase alfa was approved by the US Food and Drug Administra-
tion on the basis of 2 pivotal studies that primarily enrolled adult pa-
tients; of these, 1 study (PB-06-002) enrolled 5 pediatric patients
following a protocol amendment.
Interpretation of these study ﬁndings is limited by the small number
of patients, which precluded analysis of variance of changes from base-
line and comparisons between doses. This ERT study is unique in that it
focuses exclusively on pediatric patients with GD. Positive results found
in the study are highly consistent with the body of data from N20 years
of clinical research showing that pediatric and adult patients with Type
1 GD respond similarly to ERT.
In this extension study, taliglucerase alfa therapy administered to 15
pediatric patients with GD demonstrated improvements in visceral and
hematologic parameters and in biomarkers in treatment-naïve patients
and maintenance of disease stability in patients switched from imiglu-
cerase to taliglucerase alfa. Treatment was well tolerated, and no new
safety signals emerged.Disclosures
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